Spyre Therapeutics stock slides 6.6% after New Year session; $30 level and 2026 trial data in focus
NEW YORK, January 3, 2026, 20:15 ET — Market closed Spyre Therapeutics, Inc. shares fell 6.6% on Friday to $30.58, finishing the first U.S. trading day of 2026 near the lower end of the session’s $30.11-$33.31 range. The stock remains below its 52-week high of $34.49 after trading about 889,000 shares, while biotech benchmarks were little changed. The slide stands out because small-cap biotech names can swing sharply when investors reset positioning at the start of the year, especially after thin holiday liquidity. With little fresh company news since the last quarterly update, traders are leaning more heavily on macro